Agios Pharm (US:AGIO) — Company Overview, News & Financial Data
Agios Pharm is dedicated to developing therapeutics for cancer and rare genetic disorders, emphasizing precision medicine approaches.
Agios Pharm
Agios Pharm (NASDAQ:AGIO) focuses on the discovery and development of therapeutics in the fields of cancer and rare genetic disorders. With a commitment to leveraging scientific advances to offer new treatment options, Agios has initiated various projects aimed at targeting cellular metabolism and precision medicine. Its objectives include advancing its pipeline of novel drug candidates through clinical trials, with the goal of improving patient outcomes in areas with unmet medical needs. Emphasizing collaboration with healthcare professionals and regulatory bodies, Agios aims to bring transformative therapies from the lab to the bedside, ensuring access to innovative treatments for patients worldwide.
Snapshot
Operations
Products and/or services of Agios Pharm
- Mitapivat, first-in-class therapy for adults with pyruvate kinase (PK) deficiency to improve hemoglobin levels and reduce transfusion need.
- Research in oncology focusing on genetically defined diseases with a pipeline targeting metabolic pathways for cancer treatment.
- Collaborations with biotech and pharmaceutical companies to accelerate the development and commercialization of novel therapeutics in areas of high unmet medical need.
- Advancements in rare hematologic diseases, exploring novel therapeutic approaches for conditions with limited treatment options.
- Development of a next-generation PK activator designed to offer a more potent and selective treatment option for PK deficiency.
- Continuation and expansion of patient assistance programs aiming to ensure access to treatments for underprivileged patients.
Agios Pharm executive team
- Mr. Brian M. Goff M.B.A.CEO & Director
- Ms. Cecilia JonesChief Financial Officer
- Mr. James William BurnsCorporate Secretary & Chief Legal Officer
- Dr. Sarah Gheuens M.D., Ph.D.Chief Medical Officer and Head of Research & Development
- Ms. Tsveta MilanovaChief Commercial Officer
- Dr. Lewis clayton Cantley Ph.D.Co-Founder
- Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.Co-Founder
- Dr. Craig B. Thompson M.D.Co-Founder
- Dr. Shin-San Su Ph.D.Co-Founder
- Mr. T. J. WashburnVP, Controller & Principal Accounting Officer